RBC Capital Maintains an 'Outperform' on Regeneron Pharma (REGN); Agreement With Roche Better Than Expected

RBC Capital maintains an 'Outperform' on Regeneron Pharma (NASDAQ: REGN) price target of $70.00.

RBC analyst, Jason Kantor, feels the recent patent litigation settlement with Roche (OTC: RHHBY), for the eye drug, Eylea, 'Appears Reasonable'.

Kantor sees the settlement as a positive step which may lead to resolution of disagreement over cancer use (as brand name Zaltrap), which is contrary to some other analysts, who had expected worse outcome, ongoing litigation or possible injunction.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $55.43 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery